article thumbnail

Validation of an Administrative Knee Osteoarthritis Severity Index in a Veterans Health Affairs Cohort [Big data]

Annals of Family Medicine

The Osteoarthritis Severity Index (OASI) was developed to inform clinical trajectory of knee OA toward TKA and was previously created and validated in a nationally distributed, general population cohort of EHR data. The first OA diagnosis in record must occur from 2009-2014 and index date is OA diagnosis date.

Diagnosis 130
article thumbnail

The Approach to Chest Pain with Dr. Chris Migliore

Louisville Lectures

After, he reviews elements of the chest physical exam and finally, he reviews the fundamentals of clinical reasoning concerning chest pain. He served as an Assistant Professor at Loyola University while completing his MD at Rush Medical College in Chicago, IL, where he graduated in 2014.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Here We Go Again

Adventures of a Sick Doctor

I opened my diary (an actual physical book, not Outlook) and the silver ribbon is firmly stuck in the week of Wednesday 22nd May. Must have had a rough clinic, I supposed; a family of 4 had gone in before me, and that is never good. I am catching up on various emails and tasks that I have been ignoring for the past few weeks.

GP 100
article thumbnail

FDA’s Issues Draft Guidance on Accelerated Approval: A Substantial Evidentiary and Procedural Overhaul to this High-Profile Pathway

FDA Law Blog

Since that time, it was formalized in FDA regulations (21 CFR 314 Subpart H) in 1992, codified in the Food, Drug, & Cosmetic Act by FDAMA (21 USC 356(c)) in 1997, revised by FDASIA in 2012, and described in guidance, most importantly, in the 2014 Expedited Programs for Serious Conditions Drugs and Biologics (2014 Guidance).

Clinic 64
article thumbnail

A Question 30 Years in the Making: Would a Final LDT Rule Withstand Judicial Scrutiny?

FDA Law Blog

Regulating LDTs: A Long and Winding Road In what might sound to some like protesting too much, the PR invokes FDA’s longstanding assertion that IVDs “manufactured” by laboratories are medical devices and that clinical laboratories that develop tests are acting as manufacturers. FDA’s position is, however, only one side of the story.

article thumbnail

Surely You Must be Kidding, PTO?!? “No, and Don’t Call Me Shirley!” – The Seemingly Slapstick (But Yet Unfunny) World of Recent Patent Term Extension Decisions (PART 2)

FDA Law Blog

A surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign or other measure that is thought to predict clinical benefit but is not itself a measure of clinical benefit. Drug companies are still required to conduct studies to confirm the anticipated clinical benefit.

Clinic 59
article thumbnail

Not “burnout,” not moral injury—human rights violations

Pamela Wible MD

(Published 3/18/19, updated 6/20/25) What Is Physician “Burnout”—and Why It Matters Physician “burnout” is a state of emotional, physical, and mental exhaustion caused by prolonged stress in the medical workplace. So why are physicians experiencing physical and mental collapse from overwork?